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Abstract
Background: Antiretroviral therapy (ART) for HIV infection reconstitutes the immune system and improves survival.
However, the rate and extent of CD4+ T cell recovery varies widely. We assessed the impact of several factors on immune
reconstitution in a large Kenyan cohort.
Methodology/Principal Findings: HIV-infected female sex workers from a longitudinal cohort, with at least 1 year of pre-
ART and 6 months of post-ART follow-up (n=79), were enrolled in the current study. The median pre-ART follow-up was
4,040 days. CD4 counts were measured biannually and viral loads where available. The median CD4 count at ART initiation
was 180 cells/ul, which increased to 339 cells/ul at the most recent study visit. The rate of CD4+ T cell increase on ART was
7.91 cells/month (mean=13, range 225.92 to 169.4). LTNP status prior to ART initiation did not associate with the rate of
CD4 recovery on ART. In univariate analyses, associations were observed for CD4 recovery rate and duration of pre-ART
immunosuppression (r=20.326, p=0.004) and CD4 nadir (r=0.284, p=0.012). In multivariate analysis including age, CD4
nadir, duration of HIV infection, duration of pre-ART immunosuppression, and baseline viral load, only CD4 nadir (p=0.007)
and not duration of immunosupression (p=0.87) remained significantly associated with the rate of CD4 recovery.
Conclusions/Significance: These data suggest that prior duration of immune suppression does not predict subsequent
recovery once ART is initiated and confirm the previous observation that the degree of CD4 depletion prior to ART initiation
is the most important determinant of subsequent immune reconstitution.
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Introduction
Since access to ART to treat HIV-1 infection has increased, life
expectancy for people living with HIV has increased dramatically,
from 5–10 years in the absence of treatment, to more than 25
years following HIV infection if treated appropriately [1]. ART
decreases the risk of opportunistic infections following suppression
of HIV replication, in conjunction with reconstitution of blood
CD4+ T cell counts, partially reversing the hallmark immunode-
ficiency that develops during AIDS [2,3]. This immune recovery
means that co-infection prophylaxis can be safely discontinued in
most successfully treated individuals [4].
However, not all individuals on ART reconstitute CD4+ T cells
at the same rate, or to the same extent. As such, as many as 30% of
patients who start ART are classified as immunological non-
responders [5]. Factors that predict of poor immune reconstitution
include a lower CD4 nadir [6,7], older age [8], increased immune
activation [9,10], altered T cell homeostasis [7,11,12], markers of
microbial translocation [13], and HIV co-receptor usage [14].
One US-based study demonstrated that individuals with a lower
baseline CD4 count at the time of ART initiation achieved less
immune reconstitution than those in the higher CD4 strata, and
this was associated with reduced naı ¨ve:memory CD4 cell and
CD4:CD8 cell ratios [15]. To date, of many factors associated with
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consistent predictor of subsequent immune reconstitution. As a
result, absolute blood CD4+ T cell count is the key determinant in
the timing of ART initiation, with current World Health
Organization guidelines suggesting that treatment should start
before CD4#350/ul.
Rates of CD4+ decline are variable, and in the absence of ART
some individuals remain relatively well for long periods despite low
CD4+ T cell counts. In addition, some subjects can survive for
several years with low CD4 counts. We hypothesized that prior
HIV disease progression status and/or duration of pre-ART
immunosuppression (defined as the length of time with CD4#200
prior to ART initiation) would constitute additional independent
predictors of poor immune reconstitution on ART, in addition to
the nadir CD4+ T cell count, and might need to be considered by
ART providers.
Methods
We examined this question in a longitudinal female sex worker
cohort where an ART program was initiated in 2005 as a part of
the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR).
All subjects gave informed written consent prior to participation in
the study, and Institutional Review Boards at Universities of
Manitoba and Toronto, and Kenyatta National Hospital (Nairobi,
Kenya), approved the study. Testing of viral loads was not
standard of care in this clinic during the time that the study was
conducted, though CD4 counts were typically measured twice
annually. All patients in the study received the standard first-line
therapy of Triomin (3TC, D4T, NVP). At the time of analysis, 177
subjects were receiving ART through this program. Because the
aim was to determine factors influencing the rate of CD4+ T cell
recovery on ART, we included only those participants with at least
365 days of pre-ART follow-up and 180 days of post-ART follow-
up (n=79). Participants were called long-term non-progressors
(LTNP) if they had been HIV+ for .10 years with CD4 counts
.500 cells/ul. Median HIV-positive follow-up prior to ART
initiation was 4,448 days (mean 4,040, range 462–7,922 days), and
median follow-up post-ART initiation was 697 days (mean 758,
range 187–2,105 days). Univariate correlations were preformed
using Spearman’s Rank Correlation. Multivariate analyses includ-
ed Linear Regression with CD4 recovery/month and CD4
recovery as independent variables, and controlling for a number
of variables predicted to have an effect of the rate of CD4 recovery
following ART initiation (described below).
Results
Most subjects showed evidence of a CD4+ T cell increase after
ART initiation; the median CD4 count at ART initiation was 180
cells/ul (mean 211, range 3–851 cells/ul), and this increased to
339 cells/month at the most recent available CD4 count. The total
duration of ART was correlated with total CD4 count recovery
(r=0.48, p,0.0001, Spearman rank correlation). The rate of
CD4+ T cell increase on ART was 7.91 cells/month (mean=13,
range 225.92 to 169.4). This rate slowed significantly over time, as
demonstrated by the inverse relationship between recovery/month
and length of time on ART (r=20.36, P,0.0001). This reflects
the more rapid recovery of CD4 cells early in ART, as has been
previously described [5].
We investigated the association of several factors with the rate of
CD4 recovery, including age, CD4 nadir (defined as second lowest
CD4 count), baseline VL (available for 60/79 participants),
duration of pre-ART immunosuppression, duration of time with
HIV infection, and prior status as a long-term non-progressor
(HIV+ for $10 years with CD4 $500). Of subjects with adequate
pre- and post-ART follow-up, we identified several ‘‘prior’’
LTNPs (n=10). Although LTNPs had a trend towards a higher
CD4 Nadir (median 239 vs. 160 cells/ul, p=0.137), no differences
in the rate of CD4 recovery following ART were observed
(Figure 1A, p=0.25, Mann Whitney U test). We then calculated
the time from the first CD4 count #200/ul to ART initiation, and
correlated this to the subsequent rate of immune reconstitution.
Since an ART program was initiated in this cohort 20 years after
its inception (1985–2005), immunosuppression prior to ART
initiation was common in this population, ranging from 0 to 5,357
days from first CD4,200 to ART initiation (mean 1,568 days,
median 896 days). While no correlation was observed between
duration of pre-ART immunosuppression and total CD4 recovery,
immunosuppression was inversely correlated to the rate of CD4
recovery (Figure 1B, r=20.326, p=0.004). In univariate
analyses, subjects with longer duration of pre-ART immunosup-
pression were also older (r=0.326, p=0.004) and had a lower
CD4 nadir (r=20.652, p,0.001). As expected, there was also an
association between CD4 nadir and the rate of CD4 recovery
(Figure 1B, r=0.284, p=0.012).
Because many factors are known to influence the CD4
reconstitution on ART, we used linear regression to determine
which variables were independently associated with the rate of
CD4 recovery. In a model that included CD4 nadir, age, baseline
viral load, time with HIV infection, and time with low CD4 counts
prior to ART initiation, only CD4 nadir remained significantly
associated with a lower rate of CD4 recovery (Figure 1C,
p=0.007). Duration pre-ART immunosuppression was no longer
associated with the subsequent rate of CD4 recovery in this model
(p=0.87). To determine whether the overall extent of CD4
recovery might be predicted by duration of pre-ART immuno-
suppression, we also ran similar models using final CD4 count was
used as the main outcome of ART recovery, and obtained similar
results (not shown).
Because CD4 counts increase more dramatically in the early
stages of ART, we also analyzed our data by CD4 gains made over
the first year (‘‘early’’ recovery) and those made during the
remainder of follow-up (late recovery). Although the previous
associations were not observed with early recovery, linear
regression analyses also found that only CD4 nadir was associated
with late CD4 recovery rate (p=5610
25, data not shown).
Discussion
ART increases the length and quality of life of HIV-infected
subjects by reversing the immunodeficiency characteristic of
AIDS, but there is heterogeneity in the rate and extent to which
immune recovery is realized. In the present study, we evaluated
whether prior disease progression status (LTNP) or duration of
pre-ART immunosuppression predicted an altered rate of
recovery following ART initiation in a cohort where ART was
scarcely available from 1985–2004. We based this hypothesis on
the rationale that LTNPs and/or patients with limited amounts of
time with low CD4 counts would better retain key immunological
features, such as lymphoid architecture and T cell homeostasis,
and this in turn would allow their CD4+ T cell counts to recover
more rapidly. A second possibility is that whatever factors caused
these subjects to be LTNPs in the first place may lead to a more
rapid CD4 constitution once viral load was suppressed by ART. In
contrast, a recent study of HIV controllers placed on ART showed
that these individuals reconstituted CD4+ T cells slower than
average, possibly due the their longer time of infection prior to
ART initiation [16]. However, in our study, while the duration of
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PLoS ONE | www.plosone.org 2 July 2010 | Volume 5 | Issue 7 | e11434Figure 1. Correlations of pre-ART HIV disease progression and subsequent immune reconstitution following ART initiation in a Kenyan
female sex worker cohort. A) Prior disease progression status does not correlate with the rate of CD4 recovery. Long-term non-progressors (LTNPs) are
compared to normal progressors (those who did not meet the definition of LTNP). B) In univariate analyses, re-ART duration of immunosuppression
(CD4,200) was inversely associated with CD4 recovery/month (r=20.326, p=0.004), while CD4 nadir correlated with CD4 recovery/month (r=0.284,
p=0.012).Onx-axisiseitherpre-ARTdurationofimmunosupression(days)orCD4nadir,whilerateofCD4recoveryisonthey-axis(increaseincells/month).
C) CD4 nadir (p=0.007), but not length of immunosuppression (p=0.873), was associated with the rate of CD4 recovery in multivariate analysis.
doi:10.1371/journal.pone.0011434.g001
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subsequent CD4 recovery in univariate analysis, the only
independent predictor of slow recovery in multivariate models
was CD4 nadir. Therefore, these data confirm the previous
observation that the degree of CD4 depletion prior to ART
initiation is the most consistent determinant of subsequent immune
reconstitution, representing one of the first studies to confirm this
in sub-Saharan Africa. These data also suggest that once a patient
progresses to a certain level of CD4 depletion, it may not be as
critical for how long they have been at that level, perhaps because
at this point, substantial immunological damage has already
occurred.
Given recent studies showing that starting ART at higher CD4
counts ($350–500/ul) is both clinically advantageous and leads to
improved immune constitution [17,18], the current data add to
the growing body of knowledge that delaying ART may severely
limit the clinical impact of therapy. Because delayed or lack of an
immunological response to ART is multi-factorial [5], further
investigations are needed to understand what influences better
response to ART, to early on identify patients whose benefit from
starting ART might be diminished, and to develop alternative
therapeutic strategies. Furthermore, given the late presentation of
many HIV-infected individuals to ART programs in the
developing world, these data emphasize the need to further
promote HIV testing and counseling in order to facilitate earlier
ART initiation, not only to potentially prevent further transmis-
sion [19], but also to maximize clinical benefit to the patient.
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